In this episode, hosts Jim Mazzo and John A. Hovanesian, MD, FACS, discuss the latest news in eyecare, then speak with Eric Rosenberg, DO, about the current state and future of digital ophthalmology. Intro :10 Brief recap of episode 2 with Nicole Fram :55 News and Notes 1:31 Generic of Allergan’s Restasis by Mylan Pharmaceuticals and discussion of generics in the ophthalmic space 2:05 Aramis Biosciences in phase 2 neuromodulator dry eye program and discussion of dry eye 5:12 Jim discusses Aetna’s prior authorization for cataract surgery 6:54 Bilateral same day cataract surgery discussion 8:48 Eric Rosenberg, DO, introduction 10:48 What is digital? What is the meaning of digital? 11:38 Goals of the Digital Ophthalmic Society 17:33 Barriers to adoption of digital 22:34 What will DOS be discussing at Eyecelerator@ASCRS? 23:56 What Rosenberg hopes the DOS will achieve in the future 27:38 Thank you, Eric 29:42 Roger Ohanesian to receive Chang/Crandall Humanitarian Award at ASCRS 30:01 Sneak peek at the next episode 32:18 For more information: John A. Hovanesian, MD, FACS, is a faculty member at the UCLA Jules Stein Eye Institute and in private practice at Harvard Eye Associates in Laguna Hills, California. Jim Mazzo sits on numerous ophthalmic industry corporate boards and committees after serving in executive roles with Allergan, Avellino Labs, Carl Zeiss and AMO. Eric Rosenberg, DO, is a cornea, cataract, and refractive surgeon at SightMD. We’d love to hear from you! Send your comments/questions to [email protected]. Follow John Hovanesian on Twitter @DrHovanesian. You can reach Dr. Rosenberg via email at [email protected]. To learn more about the DOS, visit: https://www.digitalophthalmicsociety.com/. Disclosures: Hovanesian consults widely in the ophthalmic field and specifically with Alcon, Ivantis and Sight Sciences. Mazzo reports being an adviser for Anivive Lifesciences, Avellino Labs, Bain Capital, CVC Capital and Zeiss; executive chairman of Neurotech, Preceyes BV and TearLab; and sits on the board of Centricity Vision, Crystilex, IanTech, Lensgen and Visus. Healio could not confirm relevant financial disclosures for Rosenberg at the time of publication.